| dc.contributor.author | Yilmaz, Mesut | |
| dc.contributor.author | Tural, Deniz | |
| dc.contributor.author | Oz, Buge | |
| dc.contributor.author | Tacar, Seher Yildiz | |
| dc.date.accessioned | 2021-12-10T12:56:43Z | |
| dc.date.available | 2021-12-10T12:56:43Z | |
| dc.identifier.citation | Tacar S. Y. , Yilmaz M., Oz B., Tural D., "Crizotinib for c-MET-amplified advanced NSCLC: a single-center experience", TUMORI JOURNAL, 2021 | |
| dc.identifier.issn | 0300-8916 | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.other | av_e35ace45-8898-4786-a326-fd4583675f55 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/175045 | |
| dc.identifier.uri | https://doi.org/10.1177/03008916211009303 | |
| dc.description.abstract | Introduction: Lung cancer is the most common cause of cancer-related death in the world. Changes in the treatment of metastatic lung cancer in recent years have made targetable mutations gain importance. MET alteration is one of these driver mutations and crizotinib is a tyrosine kinase inhibitor used in therapy. | |
| dc.language.iso | eng | |
| dc.subject | Onkoloji | |
| dc.subject | Oncology | |
| dc.subject | Health Sciences | |
| dc.subject | Dahili Tıp Bilimleri | |
| dc.subject | İç Hastalıkları | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | Tıp | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | Klinik Tıp | |
| dc.subject | ONKOLOJİ | |
| dc.title | Crizotinib for c-MET-amplified advanced NSCLC: a single-center experience | |
| dc.type | Makale | |
| dc.relation.journal | TUMORI JOURNAL | |
| dc.contributor.department | Bakirkoy Sadi Konuk Training & Res Hosp , , | |
| dc.contributor.firstauthorID | 2703073 | |
